Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$11.59 USD
+1.12 (10.70%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.50 -0.09 (-0.78%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DYN 11.59 +1.12(10.70%)
Will DYN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
Other News for DYN
Dyne Therapeutics trading resumes
Dyne Therapeutics trading halted, volatility trading pause
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News
Dyne Therapeutics price target lowered by $21 at Oppenheimer, here's why
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-251